Filed 26 Jan 2026
Last verified 12 Oct 2026Offering in progress. A listing date has not been announced, and proposed terms may change.
Company overview
Option Therapeutics is a clinical-stage company focused on liver disease. Its investigational candidate BIV201 is continuous infusion terlipressin and is being developed to treat debilitating and life-threatening liver disease.
- Company country
- United States
Offering details
Base offering, before overallotment
- Exchange
- NYSE American
- Ticker
- OPTN
- Shares offered
- 1,818,182
- Shares after offering
- 5,000,000
- New shares
- 1,818,182
- Existing shares sold
- 0